These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24173694)

  • 61. Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice.
    Kim HK; Hsieh R; Chan A; Yu S; Han B; Gao Y; Baños A; Ying X; Burke TA; Keefe DM
    Support Care Cancer; 2015 Jan; 23(1):293-300. PubMed ID: 25142702
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
    Navari RM
    J Natl Compr Canc Netw; 2007 Jan; 5(1):51-9. PubMed ID: 17239326
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
    Chiu L; Chow R; DeAngelis C; Lock M; Simone CB
    Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The emerging role of olanzapine in paediatric CINV control: A review.
    Barušić AK
    Medicine (Baltimore); 2022 Dec; 101(50):e32116. PubMed ID: 36550859
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study.
    Keefe DM; Chan A; Kim HK; Hsieh RK; Yu S; Wang Y; Nicholls RJ; Burke TA
    Support Care Cancer; 2015 Jan; 23(1):253-61. PubMed ID: 25115893
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Olanzapine for the Treatment of Breakthrough Vomiting in Children Receiving Moderate and High Emetogenic Chemotherapy.
    Teotia N; Jain S; Kapoor G; Koneru S
    Indian Pediatr; 2020 Nov; 57(11):1069-1070. PubMed ID: 33231177
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
    Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
    Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
    [TBL] [Abstract][Full Text] [Related]  

  • 69. 2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.
    Dupuis LL; Sung L; Molassiotis A; Orsey AD; Tissing W; van de Wetering M
    Support Care Cancer; 2017 Jan; 25(1):323-331. PubMed ID: 27565788
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Outcomes of chemotherapy-induced nausea and vomiting guideline adherence in pediatric and adult patients: a systematic review.
    Renaux Torres MC; Robinson PD; Sung L; Dupuis LL;
    Support Care Cancer; 2024 Jun; 32(7):455. PubMed ID: 38913170
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
    Navari RM
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):715-24. PubMed ID: 15485308
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
    Navari RM
    Expert Opin Pharmacother; 2009 Mar; 10(4):629-44. PubMed ID: 19284365
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Granisetron vs dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study.
    Tan M; Xu R; Seth R
    Curr Med Res Opin; 2004 Jun; 20(6):879-82. PubMed ID: 15200746
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Genetic Influence on Chemotherapy-Induced Nausea and Vomiting: A Narrative Review.
    Kiernan J
    Oncol Nurs Forum; 2016 May; 43(3):389-93. PubMed ID: 27105200
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy.
    Hashimoto H; Abe M; Yanai T; Yamaguchi T; Zenda S; Uchitomi Y; Fukuda H; Mori M; Iwasa S; Yamamoto N; Ohe Y
    Jpn J Clin Oncol; 2018 Oct; 48(10):950-952. PubMed ID: 30124989
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients: a randomized controlled study.
    Mukhopadhyay S; Kwatra G; Alice K P; Badyal D
    Support Care Cancer; 2017 Jan; 25(1):145-154. PubMed ID: 27591991
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study.
    Patel P; Lavoratore SR; Flank J; Kemp M; Vennettilli A; Vol H; Taylor T; Zelunka E; Maloney AM; Nathan PC; Dupuis LL
    Support Care Cancer; 2020 Feb; 28(2):933-938. PubMed ID: 31177392
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Olanzapine for nausea and vomiting.
    Licup N
    Am J Hosp Palliat Care; 2010 Sep; 27(6):432-4. PubMed ID: 20508243
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.
    Musso M; Scalone R; Bonanno V; Crescimanno A; Polizzi V; Porretto F; Bianchini C; Perrone T
    Support Care Cancer; 2009 Feb; 17(2):205-9. PubMed ID: 18839220
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Chemotherapy-induced nausea and vomiting in the treatment of gastrointestinal tumors and secondary prophylaxis with aprepitant.
    Abbrederis K; Lorenzen S; Rothling N; Ihbe-Heffinger A; Schuster T; Peschel C; Lordick F
    Onkologie; 2009 Feb; 32(1-2):30-4. PubMed ID: 19209016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.